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ABSTRACT
Background: Bacterial pneumonia is one of the main causes of morbidity and mortality in patients 
infected by the human immunodeficiency virus (HIV). The main objective of this study was to evalu-
ate the effect of macrolide therapy in combination with a beta-lactam based empiric regimen for inpa-
tients with community-acquired pneumonia and HIV. Methods: This is a retrospective cohort study 
of hospitalized patients. Adult patients who had received treatment with ceftriaxone or ceftriaxone 
plus clarithromycin were included. Results: 76 patients met the inclusion criteria. Among baseline 
characteristics analyzed, only respiratory rate showed significant difference: patients who had received 
clarithromycin were more likely to have a respiratory rate > 30/min than patients who received only 
ceftriaxone (64% versus 36%, p = 0.03). ICU admission was the only outcome that showed a significant 
difference, more frequent in the ceftriaxone plus clarithromycin group (45% versus 20%, p = 0.03). 
Conclusions: This study does not support the addition of a macrolide to a beta-lactam based regimen 
in HIV-infected patients. This is probably related to the patients’ immunodeficiency status, which im-
pairs the immunomodulatory properties of the macrolides.
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INTRODUCTION
Bacterial pneumonia is one of the main caus-
es of morbidity and mortality in patients in-
fected by the human immunodeficiency virus 
(HIV).1,2 Its incidence has decreased after the 
introduction of highly active antiretroviral 
therapy (HAART);3,4 however, these patients 
still have a higher risk of acquiring this type of 
infection, when compared to the general popu-
lation,3 in addition to having higher rates of in-
vasive pneumococcal disease5 and mortality.6,7
The etiology of community-acquired pneu-
monia (CAP) in HIV-infected patients is simi-
lar to that of immunocompetent patients, with 
the main agent being Streptococcus pneumo-
niae. Infections by Gram-negative bacteria (in-
cluding Haemophilus influenzae, Pseudomonas 
aeruginosa and Legionella pneumophila, among 
others) are common, as well as by Staphylococ-
cus aureus.1,2,3,6
The following are considered risk factors 
for CAP in HIV-infected patients: low socio-
economic level, smoking, alcohol consump-
tion, use of intravenous (IV) drugs, comorbidi-
ties (including cardiovascular disease, kidney 
disease or liver cirrhosis), malnutrition, low 
CD4+ T-cell counts (CD4 < 200 cells/µL), HIV 
replication and lack of HAART.2
Regarding prevention, the role of the anti-
pneumococcal vaccine in HIV-infected pa-
tients is yet to be defined, as the studies have 
shown controversial results.8,9 Moreover, 
prophylaxis with sulfamethoxazole-trimetho-
prim (SMX-TMP) is a disputable question, as it 
seems to prevent bacterial pneumonia only in 
patients who are not on HAART.1,3
To date, some proposals have been made 
regarding the severity assessment of a pneu-
monia episode in an HIV-infected patient; 
however, none of them have been validated 
in this group of patients.2 The Pneumonia Se-
verity Index (PSI) consists of interesting rules 
that can predict mortality in HIV-infected 
patients.10 Another interting severity score is 
the CURB-65, adopted by the Brazilian Con-
sensus of CAP due to its simplicity11 (patients 
are considered severe when they have a score 
of IV or V at PSI or a score ≥ 3 at CURB-65).
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Another strategy to predict severity is to combine the 
scores with the CD4 count, as patients with CD4 counts 
< 200 cells/µL have higher mortality. Therefore, patients with 
CD4 < 200 cells/µL or high severity scores would be considered 
severe cases.2,10
Patient severity assessment is important for decision-mak-
ing regarding the type of treatment and where the latter must be 
carried out. In fact, choosing the empiric treatment for bacte-
rial pneumonia in HIV-infected patients is a great challenge, as 
most studies and consensus are directed at immunocompetent 
patients. 
Moreover, the studies that deal with the choice of empiric 
therapy for CAP are heterogeneous regarding the compared 
regimens, the population included in the study, and the ana-
lyzed outcomes. Some studies have a group of patients with im-
munodeficiencies, but none of them particularly assessed HIV-
infected patients.12-14 
There is evidence of decreased mortality in patients 
treated with hospital-based regimens that included the 
combination of beta-lactams and macrolides, when com-
pared to other regimens.14 Other studies have demon-
strated benefits with regimens that contain macrolides, 
when compared to regimens without this class of antibiotic 
agent.12,15 Additionally, the benefit of combined therapy 
over monotherapy have been demonstrated.13 
Considering that, to date, there is no consensus regarding 
the best empiric therapy for HIV-infected patients admitted 
to the hospital due to CAP, this study was carried out with the 
objective of assessing the impact of combining a macrolide to 
the beta-lactam therapy in this population. For that purpose, the 
primary outcome analyzed was mortality during hospital stay. 
METHODS
This a retrospective cohort study of adult HIV-infected in-
patients with CAP admitted to Instituto de Infectologia Emí-
lio Ribas, a tertiary teaching hospital in the city of São Paulo, 
state of São Paulo, Brazil.
Records of patients older than 18 years, admitted from 
January 1st, 2007 to December 31st, 2007, were selected for 
the study. Were reviewed the records of patients that had on 
admission a primary diagnosis of HIV-infection (CID-10: 
B20-B24) and a secondary diagnosis of pneumonia (CID-
10: J10 to J18.9) or vice-versa. For patients admitted more 
than once during the study period, only the first hospitaliza-
tion was considered.
Patients that had at least one symptom of acute lower 
respiratory tract disease at admission (coughing, expecto-
ration, dyspnea or chest pain) and who received CAP-di-
rected therapy consisting of ceftriaxone or ceftriaxone plus 
clarithromycin, initiated within 24 hours of admission, were 
included in the study. 
Exclusion criteria were: (I) hospital admission during the 
14-day period prior to admission; (II) diagnosis of tuber-
culosis or starting empiric treatment with anti-tuberculosis 
agents within the first 24 hours after admission; and (III) 
CAP-directed therapy consisting of antibiotic agents other 
than ceftriaxone and/or clarithromycin. It is noteworthy that 
patients who received empiric treatment for pneumocysto-
sis were not excluded from the study. 
With the objective of characterizing and comparing 
the two study groups, the following information was ob-
tained from the patients’ records: demographic charac-
teristics (age, sex, resident in public shelter, support or re-
tirement home), habits and addictions (smoking, IV drug 
use, inhaled drug use), data regarding the HIV (use of 
HAART, CD4, anti-pneumococcal vaccine, prophylaxis 
with SMX-TMP), presence of comorbidities (neoplasms, 
liver disease, heart failure, systemic arterial hyperten-
sion, previous cerebrovascular accident, previous neuro-
toxoplasmosis, diabetes, kidney disease) and admission 
data: clinical [mental confusion, respiratory rate (RR), 
systolic blood pressure (SBP), diastolic blood pressure 
(DBP), body temperature (BT), heart rate (HR), pleural 
effusion], radiological (multilobar infiltrate or pleural ef-
fusion) and laboratory data (pH, urea, sodium, glucose, 
hematocrit, PaO2, satO2).
The demographic data regarding the habits and addic-
tions, related to the HIV-infection and comorbidities were 
obtained from information registered in the records as a 
whole. CD4 measurements were considered as those ob-
tained during hospitalization or up to three months before 
the admission date. Ex-smokers or ex-drug users were con-
sidered as addicted to these substances. No data on alcohol 
use were obtained. 
The primary outcome studied was mortality during hos-
pital stay and the secondary outcomes were: admission to 
the intensive care unit (ICU), total hospitalization and ICU 
length of stay. 
Statistical analysis 
Comparisons between groups were carried out by Chi-
square test for categorical variables and two-tailed Student’s 
t test for continuous variables. The p-values < 0.05 were con-
sidered statistically significant. The analyses were performed 
using the softwares Microsoft O! ce Excel 2007 and EpiInfo 
release 3.5.1.
RESULTS
A total of 251 admissions were reviewed and out of these, 
223 cases were selected, as only the first admission in the 
period was considered for the study. 
A total of 132 patients were excluded: 16 had a hospi-
tal admission up to 14 days prior to hospitalization, 30 had 
a diagnosis of tuberculosis or were put on empiric therapy 
for tuberculosis within 24 hours of admission, 36 did not 
receive an antibiotic agent within the first 24 hours of ad-
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mission, and 50 received CAP-directed therapy with other 
antibiotic agents. Additionally, 15 cases were not included 
(two had the antibiotic regimen withdrawn within the first 
24 hours of admission, one was transferred to another hos-
pital, and 12 records could not be located).
Thus, 76 patients met the inclusion criteria and were 
included in the present study. Table 1 shows patient 
characteristics, grouped according to the therapy they 
received: monotherapy with ceftriaxone (54 patients) or 
combined therapy with ceftriaxone and clarithromycin 
(22 patients).
There was no statistical difference between the 
groups regarding age, sex, type of housing, habits, ad-
dictions and radiological findings (data not shown). 
Likewise, data regarding the HIV infection and labora-
tory tests were not different between the groups. Infor-
mation regarding anti-pneumococcal vaccine was not 
available in the records. 
On physical examination, only respiratory rate (RR) was 
significantly different: more patients on macrolide (64%) 
had a RR > 30 ipm than patients on ceftriaxone alone (36%) 
[p = 0.03].
The frequency of the association with SMX-TMP was 
similar between the two groups: 41% in patients who re-
ceived ceftriaxone and 50% in patients who received ceftri-
axone and clarithromycin. 
The patients were stratified regarding severity using the 
PSI and CURB-65 scores. In the group of patients who re-
ceived ceftriaxone, 34 had the necessary information for 
classifying according to PSI and 8 of them (23%) were con-
sidered severe cases. In this same group, 52 patients were 
classified using the CURB-65 score and of these, 6 (11%) 
Table 1. Characteristics of patients who received treatment for community-acquired pneumonia with ceftriax-
one vs. ceftriaxone plus clarithromycin
  Ceftriaxone Ceftriaxone + clarithromycin p
Patients, n 54 22 
Demographic data    
 Age 40.2+-10.0 44.9+-11.1 0.11
 Male sex 35 (64.8) 16 (72.7) 0.50
 Resident of shelter, support or 
2 (3.7) 1 (4.5) 0.86
 
 retirement home
HIV-related data   
 Irregular ARVT  15/43 (34.8) 3/17 (17.6) 0.19
 CD4 < 200 25/35 (71.4) 10/15 (66.7) 0.74
 Prophylaxis with SMX-TMP 9 (16.7) 3 (13.6) 0.80
Physical examination   
 Mental status alteration 3 (5.6) 0 0.26
 RR > 30 ipm  19/53 (35.8) 14/22 (63.6) 0.03*
 SBP < 90 mmHg 7 (12.9) 3 (13.6) 0.94
 BT < 35°C or > 40°C 0/47 1/20 (5.0) 0.12
 HR > 125 bpm 9 (16.7) 2 (9.1) 0.39
Laboratory findings   
 pH < 7.35 3/45 (6.7) 1/20 (5.0) 0.80
 Urea > 65 mg/dL 11/53 (20.7) 3/21 (14.3) 0.52
 Sodium < 130 mEq/L 5/52 (9.6) 1/20 (5.0) 0.53
 Glucose > 250 mg/dL 1/50 (2.0) 1/20 (5.0) 0.50
 Hematocrit < 30% 16/53 (30.2) 4/22 (18.2) 0.28
 pO2 < 60 mmHg 18/45 (40.0) 11/20 (55.0) 0.26
 Association with SMX-TMP 22 (40.7) 11 (50.0) 0.46
Data are presented as mean ± standard or n (%). In cases that had missing data, the total number of patients included is shown 
after the symbol “/”. RR, respiratory rate; ipm, incursions per minute; SBP, systolic blood pressure; BT, body temperature; HR, 
heart rate; pO2, oxygen arterial pressure; ARVT, anti-retroviral therapy; SMX-TMP, sulfametoxazol-trimetoprim. 
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were considered severe cases. In the group of patients that 
received ceftriaxone and clarithromycin, 8 of the 16 patients 
(50%) classified according to PSI score and 4 of the 21 pa-
tients (19%) classified according to the CURB-65 score were 
considered severe cases. There was no significant difference 
between the groups. 
Table 2 shows the comparison between the two study 
groups regarding outcomes. There was no significant differ-
ence regarding mortality during hospital stay. Among the 
studied secondary outcomes, only admission to the ICU 
was significantly different, being more common in the cef-
triaxone group (45%) than the clarithromycin group (20%) 
[p = 0.03].
Analyses were repeated, after excluding the patients who 
received SMX-TMP and the results were similar. There was 
no statistical difference between the groups regarding sex, 
type of housing, existing comorbidities, habits and addic-
tions, radiological findings, laboratory data, HIV-related in-
formation and severity (according to the CURB-65 and PSI 
scores). 
At this second analysis, the patients in the group who re-
ceived ceftriaxone and clarithromycin were relatively older 
than those who received ceftriaxone alone (47.0 ± 9.5 yrs 
versus 38.9 ± 10 yrs, p = 0.03). 
Similarly to the first analysis, the only physical examina-
tion finding that showed a significant difference was RR: pa-
tients who received clarithromycin had a higher prevalence 
of RR > 30 ipm than those who received ceftriaxone alone 
(54% versus 19%, p = 0.02).
Excluding patients who were receiving SMX-TMP, there 
was no difference regarding the outcomes between the 
group who received monotherapy with ceftriaxone and the 
group who received combined therapy with ceftriaxone and 
clarithromycin.
DISCUSSION
This is the first study carried out with the objective of assess-
ing the effect of adding macrolides to beta-lactam therapy in 
HIV-infected patients. 
Of all variables analyzed, only RR was different between 
the groups: RR > 30 ipm was more prevalent in the group 
who received ceftriaxone and clarithromycin. Among the 
studied outcomes, the observed difference was a higher fre-
quency of ICU admissions in the group who received ceftri-
axone and clarithromycin.
Although the patients did not have any difference re-
garding the classification using the severity scores (CURB-
65 and PSI), the higher frequency of tachypnea at the physi-
cal examination might have been a cause of the higher rate 
of ICU admissions in the group that received ceftriaxone 
and clarithromycin. 
Several studies that assessed the general population have 
shown a decreased mortality in patients with CAP, after the 
addition of macrolides to therapy.12,14,15 This finding was not 
supported by the results of the present study, which included 
only HIV-infected patients. 
A Spanish study, carried out in 2003, assessed patients 
with bacteremia due to S. pneumoniae (without excluding 
HIV-infected patients) and demonstrated a lower mortality 
during the hospital stay in the group that received beta-lac-
tam plus macrolide (p = 0.001).14 In this study, the patients 
who had not received macrolide, had a higher incidence of 
comorbidities, particularly HIV and malignant hematologi-
cal diseases (p = 0.0002). However, the percentage of pa-
tients with HIV infection among the studied subjects was 
not reported neither was this group of patients analyzed 
separately.14 
The multicentric (international) and prospective study 
carried out in 2004, with the objective of assessing the ef-
fect on mortality of the combination of antibiotics in pa-
tients with bacteremia due to S. pneumoniae, specified the 
number of patients with HIV infection in each group. In 
the group who received combined therapy, 11.4% of 
the patients had HIV infection and in the monotherapy 
group, 37.0%; this difference was significant (p < 0.01).13 
A logistic regression analysis demonstrated that even af-
ter adjusting for HIV infection, the combined antibiotic 
therapy maintained a positive association with survival 
Table 2. Outcomes of patients who received treatment for community-acquired pneumonia with ceftriaxone vs. 
ceftriaxone plus clarithromycin
 Ceftriaxone Ceftriaxone + clarithromycin p
Patients, n 54 22 
Death during hospitalization 7 (13) 2 (9.1) 0.63
ICU admission 11 (20.4) 10 (45.5) 0.03*
ICU stay duration (days) 11.82 ± 7.44 7.8 ± 6.66 0.21
Time of hospitalization (days) 16.39 ± 15.35 14.86 ± 14.23 0.68
Data are shown as mean ± SD or n (%). ICU, intensive care unit.
Mello, Negra
266
(odds ratio: 0.10; SE 1.7; 95% CI 1.1-9.2; p = 0.028). It is 
worth mentioning that this study did report which anti-
biotic classes that comprised the combined therapy were 
responsible for its superiority.13 
The reasons why the macrolide can lead to better re-
sults in patients with CAP are: antimicrobial synergism, 
atypical microorganism coverage and immunomodulato-
ry effect. Among these, the most important is the immu-
nomodulation of the inflammatory response and the in-
terference with the pathogenicity of the etiological agent, 
as there are studies that have demonstrated the benefit of 
the therapy with macrolides even in patients with micro-
organisms resistant to this antibiotic class.15,16 
A North-American retrospective and multicentric 
study, carried out in 2009, included patients with CAP 
and severe sepsis and excluded HIV-infected patients. 
This study demonstrated a lower 30 and 60-day mortal-
ity with the use of macrolides, even among patients who 
had severe sepsis caused by a microorganism resistant to 
this antibiotic class (hazard ratio: 0.10; 95% CI: 0.02-0.49; 
p = 0.005).15
The immunomodulatory effects of macrolides are yet 
to be clarified, as there are studies that suggest interfer-
ence with neutrophil action16,17 and another study that 
demonstrates a decrease in pneumolysin production by 
Streptococcus pneumoniae.18
A study in particular demonstrates that azithromycin 
can have a biphasic effect, initially increasing the bacte-
ricidal effects of neutrophils and subsequently, when the 
microorganism has been eliminated, inducing the apop-
tosis of the latter and interrupting inflammation, leading 
to a decrease in tissue damage and time of disease.17 
It has long been known that HIV-infection leads to 
a qualitative and quantitative neutrophil dysfunction.19,20 
The protection provided by these cells in the presence of 
bacterial infection is compromised in these patients due 
to deficiencies in chemotaxis and phagocytosis, free-rad-
ical production and altered expression of cell adhesion 
molecules.20 There is also an acceleration in the apoptosis 
process of neutrophils, contributing to the dysfunction 
and decrease of this cell population.21 
The population of the present study comprises 
HIV-infected patients, only. More than two-thirds of 
the patients in both studied groups had a CD4 count 
< 200 cells/µL, demonstrating severe immunodeficiency. 
Therefore, one should expect that in the present study pa-
tients a compromised immunomodulatory effect of the 
macrolide on the neutrophil, in relation to the general 
population. This might explain why there was no benefi-
cial effect of adding macrolides in this study. 
Some limitations of the present study are caused by 
the retrospective design and, therefore, there are some in-
herent biases, such as selection errors and missing data. 
For instance, it was not possible to obtain from the medical 
records the chest X-ray reports of all cases included in the 
study, and the radiological alteration was not included as 
requisite for the diagnosis of pneumonia. 
Another important point is the choice criterion be-
tween the two types of therapy administered, which was 
decided by the emergency ward physicians and thus, it 
was not possible to know which criteria led to the differ-
ent choices. Nevertheless, we observed that the two groups 
of patients did not present any differences regarding the 
proportion of severely-ill patients, according to the clas-
sification of severity scores. 
As some patients received other types of antimicrobial 
therapy, we chose to conduct a second analysis, excluding 
patients that received SMX-TMP and we observed practi-
cally the same results. 
We conclude that although some studies have suggested the 
superiority of a beta-lactam plus macrolide regimen when com-
pared to monotherapy with a beta-lactam in the general popu-
lation, the present study does not lend support to extend this 
conclusion to HIV-infected patients. This finding is probably 
related to the patients’ immunodeficiency status. Randomized 
controlled studies, with immunological classification stratifica-
tion, are necessary to establish the impact of this therapy on the 
mortality of patients with CAP and HIV infection.
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